H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on GANX stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors including the accelerated progress in Gain Therapeutics’ clinical study for their lead asset, GT-02287. The Phase 1b clinical trial, which focuses on patients with Parkinson’s disease, has reached its enrollment target ahead of schedule, allowing for earlier analysis of biomarker data. This advancement suggests potential positive outcomes in the drug’s mechanism, which could enhance neuroprotection by stabilizing and chaperoning the enzyme through cellular compartments.
Furthermore, Selvaraju’s valuation approach incorporates a discounted cash flow model, assigning a 20% probability of regulatory approval for GT-02287. This, combined with a calculated enterprise value and a projected price target of $8 per share, supports the Buy rating. However, he also notes potential risks such as delays in clinical advancements, safety issues, and regulatory challenges, which investors should consider.
Selvaraju covers the Healthcare sector, focusing on stocks such as Anavex Life Sciences, Axsome Therapeutics, and Urogen Pharma. According to TipRanks, Selvaraju has an average return of 16.2% and a 47.47% success rate on recommended stocks.
In another report released yesterday, Scotiabank also maintained a Buy rating on the stock with a $12.00 price target.